Adult-onset Still's disease

AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19

Retrieved on: 
Thursday, September 15, 2022
LGBTQ+, Pharmaceutical, Entertainment, Teens, Infectious Diseases, Parenting, Hospitals, Children, Celebrity, Film & Motion Pictures, Biotechnology, Women, Health, Seniors, Men, General Health, Family, COVID-19, Nursing, Consumer, Other Entertainment, Music, Other Health, Licensing (Entertainment), Adult, VP, Kumail Nanjiani, Reunion, Degenerative disease, Time, Jeff Bridges, Center, PSA, COVID-19, Coma, Twitter, Love, Prevalence, Virus, The Big Sick, Immunology, Hope, Antibody, Academy Awards, Population, Life, Partnership, United States Census Bureau, Adult-onset Still's disease, Social media, Learning, Neoplasm, Government, Patient, Facebook, Cancer, Metabolism, Instagram, Vaccine, Immunodeficiency, CDC, AstraZeneca, Nasdaq, Family, JAMA, Korea Disease Control and Prevention Agency, Caregiver, Biopharmaceutical, Multimedia, Awareness, Immune system, Immunosuppression, Veni, vidi, vici, Lymphoma, Pharmaceutical industry, Film, Medical device, Bridge, LGBTQ+, Pharmaceutical, Entertainment, Teens, Infectious Diseases, Parenting, Hospitals, Children, Celebrity, Film & Motion Pictures, Biotechnology, Women, Health, Seniors, Men, General Health, Family, COVID-19, Nursing, Consumer, Other Entertainment, Music, Other Health, Licensing (Entertainment)

While it feels like life has gone back to normal for many, this community still has very real cause for concern.

Key Points: 
  • While it feels like life has gone back to normal for many, this community still has very real cause for concern.
  • View the full release here: https://www.businesswire.com/news/home/20220915005056/en/
    Up The Antibodies, a new educational campaign from AstraZeneca with Jeff Bridges and other iconic voices to help educate the immunocompromised community about added protection against COVID-19.
  • Just as Up The Antibodies aims to let immunocompromised people know they arent alone, Bridges isnt alone in this campaign.
  • Actor, producer, and Academy Award-nominated writer Kumail Nanjiani also joined the campaign, together with his wife, Academy Award-nominated writer and producer Emily V. Gordon.

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease

Retrieved on: 
Thursday, April 29, 2021
Clinical medicine, Medicine, Medical specialties, Canakinumab, Immunology, Novartis, AOSD, Interleukin 1 beta, Monoclonal antibody, Adult-onset Still's disease

b'The approval of Ilaris (canakinumab) in the treatment of adult-onset Still\'s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.\nDORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still\'s disease, including adult-onset Still\'s disease (AOSD)1.

Key Points: 
  • b'The approval of Ilaris (canakinumab) in the treatment of adult-onset Still\'s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.\nDORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still\'s disease, including adult-onset Still\'s disease (AOSD)1.
  • "We are proud to announce this latest approval for Ilaris and are hopeful that it will open the door to reimagining care for adult Canadian patients.
  • "\nIlaris is a genetically engineered high-affinity human anti-human-interleukin-1 beta (IL-1) monoclonal antibody, administered by subcutaneous injection every four weeks in the treatment of AOSD1.
  • In our quest to find new medicines, we consistently rank among the world\'s top companies investing in research and development.

CERC-007: A First in Class Fully Human Anti-LIGHT (TNFSF14) Monoclonal Antibody Licensed from Kyowa Kirin - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 23, 2020
General Health, Pharmaceutical, Health, Medicine, Clinical medicine, Medical specialties, Strategic management, Kyowa Hakko Kirin, Monoclonal antibody, Adult-onset Still's disease, SWOT analysis

"CERC-007- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets.

Key Points: 
  • "CERC-007- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • CERC-002 is a first in class fully human anti-LIGHT (TNFSF14) monoclonal antibody licensed from Kyowa Kirin Co., Ltd.
    A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Connective tissue diseases, Rare diseases, Adult-onset Still's disease, Immunology, AOSD, Arthritis, Autoimmunity, Juvenile idiopathic arthritis

Adult onset Stills disease (AOSD) is a rare inflammatory disease resulting in joint damage, high fever and rashes," said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor.

Key Points: 
  • Adult onset Stills disease (AOSD) is a rare inflammatory disease resulting in joint damage, high fever and rashes," said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor.
  • There are two major forms of the disease: adult onset Stills disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA).
  • It is in development for multiple auto-immune diseases, including Stills disease (adult onset Stills disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM).
  • CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Stills disease (adult onset Stills disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM).

TADEKINIG ALFA: A Recombinant Interleukin-18 Binding Protein (r-hIL-18BP), that Binds with High Affinity to IL-18 - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 21, 2020
Health, Pharmaceutical, Branches of biology, Medical specialties, Interleukins, Clinical medicine, Cytokines, Immunology, Adult-onset Still's disease, Inflammation, Still's disease

The "TADEKINIG ALFA - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TADEKINIG ALFA - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • "TADEKINIG ALFA- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Tadekinig alfa is a recombinant interleukin-18 binding protein (r-hIL-18BP), that binds with high affinity to IL-18, a major inflammatory mediator.

Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medicine, Arthritis, Rare diseases, Connective tissue diseases, Health sciences, Health, Adult-onset Still's disease, Still's disease, AOSD, Disease

The "Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The "Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the market trends of adult-onset Still's disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The adult-onset Still's disease (AOSD) market report provides analysis regarding current treatment practices, emerging drug-like CERC-007 (Cerecor) and potential therapies, market share of the individual therapies, historical, current, and forecasted adult-onset Still's disease market size from 2017 to 2030, segmented by seven major markets.
  • The adult-onset Still's disease epidemiology chapters provide insights about historical and current adult-onset Still's disease patient pool and forecasted trends for every seven major countries.

Global Anakinra Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 16, 2020
Health, Pharmaceutical, Medical specialties, Rare diseases, Arthritis, Clinical medicine, Connective tissue diseases, Medicine, Anakinra, Immunosuppressants, Adult-onset Still's disease, Still's disease

The "ANAKINRA - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ANAKINRA - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • "ANAKINRA- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Adult-onset Still's Disease are giving market competition to ANAKINRA and launch of late-stage emerging therapies in the near future will significantly impact the market.

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Tuesday, December 8, 2020
Medical specialties, Medicine, Clinical medicine, Multiple myeloma, Orphan drugs, Adult-onset Still's disease, Autoimmunity, Immunosuppressants, Smouldering myeloma, Tocilizumab

Elevated levels of IL-18 are correlated with poor survival in patients with multiple myeloma1, said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor.

Key Points: 
  • Elevated levels of IL-18 are correlated with poor survival in patients with multiple myeloma1, said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor.
  • Targeting and reducing IL-18 using CERC-007 may substantially benefit relapsed or refractory multiple myeloma patients.
  • Multiple myeloma is the second most common blood cancer, with approximately 140,000 patients in the United States.2 Multiple myeloma is characterized by an excess proliferation of plasma cells.
  • It is in development for multiple auto-immune diseases, including Stills disease (adult onset Stills disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM).

Global Still’s Disease Treatment Market to Reach Up To US$ 2,093.8 Million by end of 2027, Says Coherent Market Insights

Retrieved on: 
Tuesday, July 28, 2020
Biotechnology, General Health, FDA, Health, Pharmaceutical, Medicine, Arthritis, Articles, Health, Swedish Orphan Biovitrum, Adult-onset Still's disease, Connective tissue diseases, AOSD, Still's disease, Disease

The global stills disease treatment market is expected to witness significant growth, owing to increasing research & development activities and drug launches.

Key Points: 
  • The global stills disease treatment market is expected to witness significant growth, owing to increasing research & development activities and drug launches.
  • For instance, in July 2018, Swedish Orphan Biovitrum AB launched Kineret drug for the treatment of AOSD (adult-onset still's disease).
  • The global stills disease treatment market is expected to exhibit a CAGR of 4.49% during the forecast period (2020-2027), owing to increasing prevalence of stills disease across the world.
  • Global Stills Disease Treatment Market, By Treatment: